Underrecognition of clinically significant side effects in depressed outpatients

Journal of Clinical Psychiatry

Volumn 71, Issue 4, 2010, Pages 484-490

  Zimmerman, Mark ^a   Galione, Janine N ^a   Attiullah, Naureen ^a   Friedman, Michael ^a   Toba, Cristina ^a   Boerescu, Daniela A ^a   Ragheb, Moataz ^a  

^a RHODE ISLAND HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; ANTIDEPRESSANT AGENT; APLENZIN; IMIPRAMINE; PHENELZINE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; TRIMIPRAMINE; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADULT; AGED; AGITATION; ANORGASMIA; ARTICLE; BLURRED VISION; CONSTIPATION; DAYTIME SOMNOLENCE; DECREASED APPETITE; DEPRESSION; DIARRHEA; DIZZINESS; EDEMA; EJACULATION DISORDER; ERECTILE DYSFUNCTION; FATIGUE; FEMALE; FLUSHING; HEADACHE; HUMAN; INCREASED APPETITE; LIBIDO; MAJOR CLINICAL STUDY; MALE; NAUSEA; NERVOUSNESS; OUTPATIENT; PREMATURE EJACULATION; PRIORITY JOURNAL; PSYCHIATRIST; SELF REPORT; SIDE EFFECT; SLEEP; STOMACH DISEASE; SWEATING; TREMOR; TWITCHING MOTILITY; WEAKNESS; WEIGHT GAIN; WEIGHT REDUCTION; XEROSTOMIA;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AMBULATORY CARE; ANTIDEPRESSIVE AGENTS; ATTITUDE OF HEALTH PERSONNEL; ATTITUDE TO HEALTH; CHECKLIST; DEPRESSIVE DISORDER, MAJOR; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DRUG TOXICITY; FEMALE; HUMANS; MALE; MIDDLE AGED; PATIENT DROPOUTS; PERSONALITY INVENTORY; PSYCHIATRIC STATUS RATING SCALES; PSYCHIATRY; QUESTIONNAIRES;

EID: 77951061439     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.08m04978blu     Document Type: Article

References (30)

1. Burra TA, Chen E, McIntyre RS, et al. Predictors of self-reported antidepressant adherence. Behav Med. 2007;32(4):127-134.
2. Goethe JW, Woolley SB, Cardoni AA, et al. Selective serotonin reuptake inhibitor discontinuation: side effects and other factors that influence medication adherence. J Clin Psychopharmacol. 2007;27(5):451-458.
3. Bull SA, Hu XH, Hunkeler EM, et al. Discontinuation of use and switching of antidepressants: influence of patient-physician communication. JAMA. 2002;288(11):1403-1409.
4. Bolling MY, Kohlenberg RJ. Reasons for quitting serotonin reuptake inhibitor therapy: paradoxical psychological side effects and patient satisfaction. Psychother Psychosom. 2004;73(6):380-385.
5. Demyttenaere K, Enzlin P, Dewe W, et al. Compliance with antidepressants in a primary care setting, 1: beyond lack of efficacy and adverse events. J Clin Psychiatry. 2001;62(suppl 22):30-33. (Pubitemid 32937583)
6. Maddox JC, Levi M, Thompson C. The compliance with antidepressants in general practice. J Psychopharmacol. 1994;8(1):48-53.
7. Rosenberg KP, Bleiberg KL, Koscis J, et al. A survey of sexual side effects among severely mentally ill patients taking psychotropic medications: impact on compliance. J Sex Marital Ther. 2003;29(4):289-296. (Pubitemid 36807936)
8. Masand PS. Tolerability and adherence issues in antidepressant therapy. Clin Ther. 2003;25(8):2289-2304.
9. Lin EH, Von Korff M, Katon W, et al. The role of the primary care physician in patients' adherence to antidepressant therapy. Med Care. 1995;33(1):67-74.
10. Melartin TK, Rytsala HJ, Leskela US, et al. Continuity is the main challenge in treating major depressive disorder in psychiatric care. J Clin Psychiatry. 2005;66(2):220-227.
11. Hu XH, Bull SA, Hunkeler EM, et al. Incidence and duration of side effects and those rated as bothersome with selective serotonin reuptake inhibitor treatment for depression: patient report versus physician estimate. J Clin Psychiatry. 2004;65(7):959-965.
12. Sleath B, Rubin R, Huston S. Hispanic ethnicity, physician-patient communication, and antidepressant adherence. Compr Psychiatry. 2003;44(3):198-204. (Pubitemid 36597219)
13. Bent S, Padula A, Avins AL. Brief communication: better ways to question patients about adverse medical events: a randomized, controlled trial. Ann Intern Med. 2006;144(4):257-261. (Pubitemid 46768208)
14. Wallander MA, Dimenas E, Svardsudd K, et al. Evaluation of three methods of symptom reporting in a clinical trial of felodipine. Eur J Clin Pharmacol. 1991;41(3):187-196.
15. Wallin J, Sjövall J. Detection of adverse drug reactions in a clinical trial using two types of questioning. Clin Ther. 1981;3(6):450-452. (Pubitemid 11092515)
16. Montejo-González A, Liorca G, Izquierdo J, et al. SSRI-induced sexual dysfunction: fluoxetine, paroxetine, sertraline, and fluvoxamine in a prospective, multicenter, and descriptive clinical study of 344 patients. J Sex Marital Ther. 1997;23(3):176-194. (Pubitemid 27514710)
17. Greenblatt M. Controls in clinical research. Clin Pharmacol Ther. 1964;5:864-870.
18. Vanderkooy JD, Kennedy S, Bagby R. Antidepressant side effects in depression patients treated in a naturalistic setting: a study of bupropion, moclobemide, paroxetine, sertraline, and venlafaxine. Can J Psychiatry. 2002;47(2):174-180. (Pubitemid 34464559)
19. Downing RW, Rickels K, Meyers F. Side reactions in neurotics, pt 1: a comparison of two methods of assessment. J Clin Pharmacol J New Drugs. 1970;10(5):289-297.
20. Brook OH, van Hout HP, Stalman WA, et al. Nontricyclic antidepressants: predictors of nonadherence. J Clin Psychopharmacol. 2006;26(6):643-647.
21. Delgado PL. Approaches to the enhancement of patient adherence to antidepressant medication treatment. J Clin Psychiatry. 2000;61(suppl 2):6-9.
22. Demyttenaere K. Compliance during treatment with antidepressants. J Affect Disord. 1997;43(1):27-39.
23. Hunot VM, Horne R, Leese MN, et al. A cohort study of adherence to antidepressants in primary care: the influence of antidepressant concerns and treatment preferences. Prim Care Companion J Clin Psychiatry. 2007;9(2):91-99. (Pubitemid 46607462)
24. Keller MB, Hirschfeld RM, Demyttenaere K, et al. Optimizing outcomes in depression: focus on antidepressant compliance. Int Clin Psychopharmacol. 2002;17(6):265-271. (Pubitemid 35283713)
25. Mitchell AJ. Depressed patients and treatment adherence. Lancet. 2006;367(9528):2041-2043.
26. American Psychiatric Association. Practice guideline for the treatment of patients with major depressive disorder [revision]. Am J Psychiatry. 2000;157(suppl 4):1-45. (Pubitemid 30193855)
27. Trivedi MH, Daly EJ. Measurement-based care for refractory depression: a clinical decision support model for clinical research and practice. Drug Alcohol Depend. 2007;88(suppl 2):S61-S71.
28. Zimmerman M, McGlinchey JB, Chelminski I. An inadequate standard of care: lack of measurement of outcome when treating depression in clinical practice. Prim Psychiatry. 2008;15:67-75. (Pubitemid 351847591)
29. Lindstrom E, Lewander T, Malm U, et al. Patient-rated versus clinician-rated side effects of drug treatment in schizophrenia: clinical validation of a self-rating version of the UKU Side Effect Rating Scale (UKU-SERS-Pat). Nord J Psychiatry. 2001;55(suppl 44):5-69. (Pubitemid 33077023)
30. Day JC, Wood G, Dewey M, et al. A self-rating scale for measuring neuroleptic side-effects: validation in a group of schizophrenic patients. Br J Psychiatry. 1995;166(5):650-653.